MAP2K7 and influenza: Thus, short-term Vemurafenib treatment of influenza virus-infected patients exhibiting no abnormal lung physiology is not likely to induce strong side-effects based on a hyperactivated Raf/MEK/ERK pathway such as carcinoma, while showing efficient limitation of influenza replication.